BNP Paribas Financial Markets Purchases Shares of 8,876 Verve Therapeutics, Inc. (NASDAQ:VERV)

BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 8,876 shares of the company’s stock, valued at approximately $50,000.

Other institutional investors have also bought and sold shares of the company. Norges Bank bought a new stake in Verve Therapeutics during the fourth quarter valued at $441,000. Wells Fargo & Company MN boosted its position in Verve Therapeutics by 25.0% during the fourth quarter. Wells Fargo & Company MN now owns 45,422 shares of the company’s stock valued at $256,000 after acquiring an additional 9,083 shares during the last quarter. Invesco Ltd. boosted its position in Verve Therapeutics by 5.7% during the fourth quarter. Invesco Ltd. now owns 57,140 shares of the company’s stock valued at $322,000 after acquiring an additional 3,080 shares during the last quarter. Rhumbline Advisers boosted its position in Verve Therapeutics by 1.9% during the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock valued at $627,000 after acquiring an additional 2,093 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Verve Therapeutics by 14.5% during the 4th quarter. Ameriprise Financial Inc. now owns 258,873 shares of the company’s stock worth $1,460,000 after purchasing an additional 32,817 shares in the last quarter. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Price Performance

VERV opened at $4.84 on Wednesday. Verve Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $9.31. The firm has a market capitalization of $431.45 million, a PE ratio of -1.97 and a beta of 1.82. The company’s 50-day moving average is $4.46 and its 200 day moving average is $5.74.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.36. The company had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Analyst Upgrades and Downgrades

VERV has been the topic of a number of research analyst reports. Guggenheim increased their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Wall Street Zen raised shares of Verve Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Canaccord Genuity Group increased their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Royal Bank of Canada cut their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Verve Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.